Prime Medicine, Inc. (PRME) Form 8-K — Aug 6, 2026
Prime Medicine reported second quarter 2026 financial results with a net loss of $42.1 million and a cash position of $108.8 million, providing runway into 2027. The company announced regulatory clearances for PM577a in Wilson disease and a favorable arbitration resolution with Beam Therapeutics affirming rights to PM647 in Alpha-1 Antitrypsin Deficiency.
Key figures
- Eps Beat
- 0
- Revenue
- 1154000
- Guidance
- Cash, cash equivalents and investments as of June 30, 2026 will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.
- Total Debt
- 0
- Revenue Yoy
- 3.4
- Total Assets
- 249040000
- Cash Position
- 108800000
- Shares Outstanding
- 177224892
- Cash Runway
- into 2027
- Ga Expenses
- 11042000
- Rd Expenses
- 33397000
Price after filing
1 day: +3.4%7 days: +6.4%30 days: +24.2%
Close on the filing date to close N calendar days later (from $2.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.